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mt-tRNA modificationExome sequencing identified compound heterozygous mutations in the recently discovered mitochondrial
methionyl-tRNA formyltransferase (MTFMT) gene in two sisters with mild Leigh syndrome and combined
respiratory chain deficiency. The mutations lead to undetectable levels of the MTFMT protein. Blue native
polyacrylamide gel electrophoresis showed decreased complexes I and IV, and additional products stained
with complex V antibodies, however the overall steady state level of mt-tRNAMet was normal. Our data illus-
trate that exome sequencing is an excellent diagnostic tool, and its value in clinical medicine is enormous,
however it can only be optimally exploited if combined with detailed phenotyping and functional studies.
© 2013 Elsevier B.V. and Mitochondria Research Society. Open access under CC BY license.1. Introduction
Mitochondrial protein synthesis is very complex, and the pathway
requires ribosomal proteins, ribosomal assembly proteins, aminoacyl-
tRNA synthetases, tRNA modifying enzymes, tRNA methylating
enzymes and several initiation, elongation and termination factors
of translation (Rötig, 2011; Smits et al., 2010). About 150 different pro-
teins are involved in the translation of the 13 mitochondrial-encoded
proteins, illustrating the importance of mitochondrial translation in
human mitochondrial disease (Chrzanowska-Lightowlers et al., 2011;
Rötig, 2011). Most of these gene defects result in cytochrome c oxidase
(COX) deficient or ragged red fibres and biochemical multiple respira-
tory chain (RC) defect in affected organs. The clinical phenotypes are
very variable, however most presentations are early-onset, severe,
and often fatal, implying the importance of mitochondrial translation
from birth (Kemp et al., 2011). Some of these conditions affect multiple
tissues, however tissue specific manifestations have been reported for
several mt-tRNA aminoacyl synthetase or mt-tRNA modifying genes
(Chrzanowska-Lightowlers et al., 2011; Rötig, 2011).e, Newcastle University, Central
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arch Society. Open access under CC BYDue to the rapid increase in the number of nuclear genes and the
widely varying phenotypes associated with combined RC deficiency, it
is extremely difficult to select specific candidate genes for diagnostic
screening. As a consequence, sequencing the known nuclear genes af-
fectingmitochondrial protein synthesis has not been efficient in an ear-
lier study (Kemp et al., 2011). However, next generation sequencing
(NGS) has proven to be a very powerful tool in identifying nuclear dis-
ease genes in combined RC deficiency (Calvo et al., 2010). Either
analysing ~1000 genes predicted to encode mitochondrial proteins
(MitoExome) (Calvo et al., 2010; Tucker et al., 2011) or studying the
whole exome has successfully detected the causative mutations in sev-
eral families with RC deficiency (Ghezzi et al., 2012; Haack et al., 2012;
Shamseldin et al., 2012). Most of these papers report a low number of
patients with a single gene defect however some genes appear across
different cohorts, indicating the existence of somemore frequent genet-
ic defects (HennekamandBiesecker, 2012). Although characteristic clin-
ical presentations may facilitate the recognition of the phenotype in
larger patient cohorts (Steenweg et al., 2012), this is not usually the case.
Mutations in the mitochondrial methionyl-tRNA formyltransferase
(MTFMT) genewere first identified using targeted sequencing of themi-
tochondrial andnuclear encodedmitochondrial proteome (MitoExome)
in two unrelated patientswith Leigh syndrome and combined complex I
deficiency and complex IV deficiency (Tucker et al., 2011). Exome se-
quencing in a cohort of patients with complex I deficiency identified
two further patients with MTFMT deficiency, suggesting that this gene
defect may account for a relevant number of patients with combined license.
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clinical, biochemical, genetic and in vitro studies in two sisters carrying
compound heterozygous mutations inMTFMT.2. Materials and methods
2.1. Case reports
2.1.1. Patient 1
Patient 1 was included in a cohort of 52 patients with genetically
undefined combined respiratory chain deficiency (patient 12 in Kemp
et al., 2011). She is currently 16 years old, the first child of healthy
non-consanguineous German parents. She has a similarly affected
younger sister and a brother, who has normal neurological status, but
has behavioural problems. Birth and early motor development were
normal (walking by 18 months of age), however speech development
was delayed, leading to the first clinical investigations at 3 years of
age (normal chromosome analysis and EEG). She slowly developed
coordination problems over the following 3 years.
On clinical examination at 6 years of age herweight and heightwere
b3rd percentile. Therewas no ptosis or ophthalmoparesis. She hadmild
facial hypotonia, but normal vision and hearing. She had a slight dysar-
thria and speech was limited to short sentences. She had no muscle
weakness, however muscle tone was generally reduced; deep tendon
reflexes were normal and symmetric. There was a mild ataxia, causing
difficulties in tandem gait, and her fine finger movements were clumsy.
She could walk and run without help, could not jump, but learned to
ride a tricycle. Her cognitive function was slightly impaired.
Cardiac and respiratory functions were normal. Laboratory tests
were normal, except for mildly increased CSF lactate (3.3 mmol/L,
normal b2.2; serum lactate 1.5 mmol/L, normal b2.0).
Brain MRI showed mild signal abnormalities in the dorsal periven-
tricular white matter and increased signal intensities bilaterally on
T2-weighted sequences in the nucleus caudatus and putamen, although
brainstem and cerebellum were normal.
On examination at 14 years of age, she had short stature (height
b3rd percentile; weight b3rd percentile). She had a slightly ataxicTable 1
Summary of all previously reported patients compared to our patients with MTFMT mutati
Ref. Onset Age/death Clinical presentation
Previously described patients
Tucker 9 years Alive at 21 years Optic atrophy, ophthalmoparesis, speech problems,
ataxia, cognitive impairment, WPW syndrome
9 years Alive at 18 years Global developmental delay, optic atrophy, speech
problems, ataxia, cognitive impairment,
WPW syndrome
Tucker 5 years Died at 5 years Weight gain, hypertension, Cushing's disease, after
general anaesthetics seizure, respiratory failure
Haack n.d. n.d. Vertical gaze palsy, optic atrophy, tetraspasticity,
mental retardation, bladder dysfunction
Haack n.d. n.d. Developmental delay, muscular hypotonia, ataxia
Patients described in this paper
P1 3 years Alive at 16 years Developmental delay (more speech than motor),
muscular hypotonia, ataxic gait, dysarthria
P2 5 years Alive at 6 years Developmental delay (more speech than motor),
muscular hypotonia, tremor
Abbreviations: +: present, n.d.: not determined; LS: Leigh syndrome, RC: respiratory chaingait. Cognitive development was impaired — she could not read but
was able to count up to 10.
2.1.2. Patient 2
The younger sister of patient 1 had normal birth, and her motor de-
velopment was slightly delayed (crawling at 9 months of age, walking
at 22 months of age). There was a moderate delay in her speech devel-
opment (2 word sentences at 3 years of age) with mild cognitive
dysfunction. Diagnostic work-up took place at 5 years of age.
Her weight was b10th percentile, and height b3rd percentile.
Cranial nerves were normal; she had no ptosis or ophthalmoparesis,
had normal vision and hearing, but mild facial hypotonia. She had
generalised muscular hypotonia but muscle strength and deep ten-
don reflexes were normal. There was no ataxia or dysmetria, however
she had some intention tremor. She could walk and run, but could not
ride a tricycle. Her speech was limited to short sentences and she had
mild cognitive dysfunction.
She had asthma, mildly increased TSH with normal thyroid func-
tion, and heart, liver and gastrointestinal tract were normal. Because
of her short stature, growth hormone therapy was considered.
Laboratory investigations showed normal results includingmetabolic
workup, except for a moderately increased serum lactate (3.2 mmol/L,
normal b2.2). Brain MRI and MR spectroscopy at 4 years of age were
normal.
2.2. Histological and biochemical analyses of skeletal muscle
Histological and biochemical analyses of skeletal muscle were
performed at 6 years of age as previously described (Gempel et al.,
2007).
2.3. Genetic analyses
Mitochondrial DNA deletions, depletion and point mutations were
excluded in muscle DNA. Direct sequencing of POLG, EFG1, EFTu, EFTs,
MRPS16 and TRMU in blood-DNA of patient 1 was normal (Kemp et
al., 2011).ons.
Brain MRI Muscle biopsy Fibroblasts RC Mutation
LS Complexes I+IV↓ Fibroblasts
Complexes I+III+IV↓
c.626C>T
p.Arg181SerfsX5
c.382C>T/p.Arg128X
Compound heterozygous
LS n.d. n.d.
LS Complexes
I+III+IV↓
Fibroblasts
Complexes I+III+IV↓
c.626C>T
p.Arg181SerfsX5
c.374C>T/p.Ser125Leu
Compound heterozygous
LS Complex I↓
16% of normal
n.d. c.626C>T
p.Arg181SerfsX5
c.994C>T/p.Arg332X
Compound heterozygous
LS+white
matter lesion
Complex I↓
12% of normal
n.d. c.626C>T
p.Arg181SerfsX5
Homozygous
LS Histology mt
accumulation
complexes I+IV↓
Myoblast
Complexes I+IV↓
c.452C>T, p.Pro151Leu
c.994C>T, pR332X
Compound heterozygous
Normal n.d. n.d.
.
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Exome sequencing was performed in genomic DNA of patient 1 by
AROS Applied Biotechnology AS (Aarhus, Denmark) using Illumina's
TruSeq DNA Sample Prep Kit and Exome Enrichment Kit, with 100 bp
paired-end reads. Samples were processed on the Illumina HiSeq 2000
platform (Horvath et al., 2012). Sequence was aligned to the human
reference genome (UCSC hg19) using BWA and reformatted using
SAMtools. Single base variants were identified using VarScan (v2.2)
and Indelswere identified usingDindel (v1.01). The raw lists of variants
were filtered using in-house Perl scripts to identify on-target variants
that were rare with a minor allele frequency of less than 0.01 or not
present in 1000 Genomes (Feb 2012 download), dbSNP135 or in the
exome sequences of 91 unrelated and unaffected individuals. Putative
‘disease causing’ mutations were identified using MutationTaster
(http://www.mutationtaster.org/). Primer sequences used to sequence
MTFMT genomic DNA and cDNA are listed in the Supplementary
materials.
2.4. Tissue culture and mitochondrial functional studies
Cultured myoblasts of patient 1 and controls were grown in skel-
etal muscle cell growth medium and supplement mix (PromoCell)
plus 10% FBS (Gibco), 1% 200 mM L-glutamine (GIBCO) and gentami-
cin 50 μL/mL. Myoblasts of patient 1 and a control cell line were
immortalised by transduction with a retroviral vector expressing
the catalytic component of human telomerase (htert) (Lochmüller
et al., 1999).
2.4.1. Immunoblotting
SDS PAGE was performed on immortalised control and patient
myoblasts. Aliquots of total protein (5–20 μg) were loaded on 14% so-
dium dodecyl sulphate polyacrylamide gels then transferred to
polyvinylidene fluoride membranes. Membranes were subsequently
probed with the following monoclonal antibodies: β actin, 0.1 μg/mL
(SIGMA); complex IV subunit II, 1 μg/mL; complex II 70 kDA subunit,
0.1 μg/mL; and complex I NDUFB8 subunit, 0.5 μg/mL (MitoSciences).
Following incubation with horseradish peroxidase-conjugated second-
ary antibodies (Dako, Denmark A/S) detected proteins were visualised
by ECL-plus (GE Healthcare). Immunoblotting for MTFMT was per-
formed on control and patient myoblasts. Aliquots of total protein
(50–100 μg) were loaded on 14% sodium dodecyl sulphate polyacryl-
amide gels then transferred to polyvinylidene fluoride membranes.
Membranes were subsequently probed with monoclonal antibodies
for anti-MTFMT 2 μg/mL (Abcam) and complex II 70 kDA subunit,
0.1 μg/mL (Abcam), incubated with horseradish peroxidase-conjugated
secondary antibodies (Dako, Denmark A/S) and detected proteins
were visualised by ECL-plus (GE Healthcare).
2.4.2. Blue native polyacrylamide gel electrophoresis (BN-PAGE)
BN-PAGEwasperformed onmyoblasts of patient 1 and controlmyo-
blasts as previously described (Leary and Sasarman, 2009). After elec-
trophoresis activities, “in gel” assays were carried out as previously
described (Diaz et al., 2009). A Coomassie blue staining was done in
parallel to the activities as a loading control.
2.4.3. High resolution Northern blot analysis
Total RNA from 1 to 2 × 106 cultured myoblast lines was extracted
using TRIzol reagent (Life Technologies, Paisley, UK) according to the
manufacturer's instructions. High resolution Northern blot analysis of
total RNA (1 μg) was performed as previously described (Taylor et al.,
2003). The human mt-tRNAMet probe was generated using the for-
ward primer H4404 (positions 4404–4426) 5′-TAAGGTCAGCTAAATA
AGCTATC-3′ and reverse primer L4466 (positions 4466–4446) 5′-T
ACGGGAAGGGTATAACCAAC-3′. The human mt-tRNAGlu probe was
generated using the forward primer L14635 (positions14810–14791)
5′-TACTAAACCCACACTCAACAG-3′ and reverse primer H14810(positions14810–14791) 5′-GGAGGTCGATGAATGAGTGG-3′. The radio-
active signal for themt-tRNAMet probe was normalised to that of the 5S
RNA probe for each sample.
3. Results
3.1. Histological and biochemical analyses of skeletal muscle
Muscle biopsy of patient 1 at 6 years of age detected mild lipid ac-
cumulation in type I fibres. There was a subsarcolemmal accumula-
tion of mitochondria in type I fibres, but no typical ragged red fibres
(RRF) on Gomori-trichrome staining, however oxidative enzyme
staining for NADH NADH-CoQ-Oxidoreductase (NADH), succinate de-
hydrogenase (SDH) and COX showed more prominent mitochondrial
networks.
Biochemical analysis of the RC enzymes in skeletal muscle of pa-
tient 1 showed a reduction of complex I (NADH-CoQ-Oxidoreductase
(0.10 U/U citrate synthase (CS), normal range: 0.17–0.56 U/UCS) and
COX (0.7 U/UCS, normal range: 0.9–4.7 U/UCS)). The activities of
complex II, complex III and the pyruvate dehydrogenase were normal
(CS was 100 U/gNCP, normal 45–100 U/gNCP). COX activity in fibro-
blasts of patient 1 was normal (0.91 U/UCS, normal 0.4–2.1 U/gNCP).
3.2. Genetic analyses
Exome sequencing identified 462 rare variants (Fig. 1A), which
were not listed on dbSNP135 and were not found to be shared in
the 1000 genome project or in a panel of 91 in-house disease control
subjects (Horvath et al., 2012). Twenty-two of these variants were
predicted to be disease-causing (MutationTaster), but only one
gene, MTFMT contained two likely pathogenic variants (Fig. 1B).
Only variants in MTFMT, a recently described human disease gene
encoding a mitochondrial protein (Tucker et al., 2011) were con-
firmed on Sanger sequencing. Patient 1 was heterozygous for both a
missense mutation, c.452C>T, p.P151L, and a nonsense mutation,
c.994C>T, p.R332X in MTFMT. The mutations were not present in 91
in-house exomes, 128 Caucasian controls, or data from the 1000 ge-
nome project. The unaffected mother was heterozygous for the
c.994C>T, pR332X variant and the affected sibling was compound
heterozygous for both variants (Fig. 1B). DNA was not available
from the father. Sequencing of MTFMT cDNA in patient 1 showed
both changes to be present at transcript level (Fig. 1B), suggesting
that the stop mutation in the last exon does not result in nonsense
mediated decay. Direct sequencing of the MTFMT gene in 30 patients
with combined RC deficiency detected no pathogenic mutations.
3.3. Tissue culture and mitochondrial functional studies
High resolution Northern blotting showed normal steady state
level of mt-tRNAMet (Fig. 1C). Immunoblotting for MTFMT detected
no band in myoblasts of patient 1, confirming a severe decrease of
the protein (Fig. 1D). COXII and NDUFB8 were also decreased in pa-
tient 1, suggesting a deficiency in complexes I and IV respectively
(Fig. 1E). This was confirmed by BN-PAGE which showed an absence
of complex I and severe decrease in complex IV, but also detected a
number of extra bands with the complex V antibody suggesting an
unstable ATP synthase (Fig. 1F). Complex III was normal. In-gel activ-
ities were corresponding to the BN-PAGE result (Fig. 1G).
4. Discussion
Pathogenic mutations in the MTFMT gene have been reported in 2
independent patients with combined RC defect (Tucker et al., 2011)
and 2 with isolated complex I deficiency to date (Haack et al., 2012)
(Table 1). All reported patients had Leigh syndrome, however the
clinical presentation was relatively late-onset in 3 patients, 2 of
C F 
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462 25 22 15 1
41,625 9,061 5,051 810
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G 
C P1
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Complex II 70 kDa
MTFMT
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mt-tRNA-Met
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II
III
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B
Fig. 1. A) Variant numbers following analysis pipeline of BWA (Sequence Aligner); VarScan (single base variant — SBV calling); Dindel v1.01 (Indel calling). (*) SBV — VarScan pa-
rameters min. total coverage ≥5-fold, min. variant coverage ≥3-fold, min. Quality > 10; Indel — Dindel output filter min. variant coverage ≥4. (a) Variants with position within
targets (Illumina TruSeq 62 Mb) +/−500 bp, seen on both (forward & reverse) strands and (SBVs only) variant allele frequency >24%; (b) variants that match 1000 genomes
(Feb 2012) and/or dbSNP135 with minor allele frequency (MAF) >0.01; (c) rare/novel variants (MAF b 0.01) with exclusion of common variants found to be shared in an
in-house panel of 91 ʻnon-respiratory complexʼ individuals; (e) MutationTaster predictions. B) Identification of pathogenic compound heterozygous mutations in MTFMT. Electro-
pherogram of MTFMT DNA and cDNA sequence of patient 1 and a control. C) High resolution Northern blotting detected normal mt-tRNAMet steady state levels in myoblasts of pa-
tient 1. For comparison we show also mt-tRNAGlu and 5S rRNA. D) SDS-PAGE immunoblotting analysis in myoblasts of patient 1 showed no detectable MTFMT protein. Complex II
70 kDa subunit antibody was used as a loading control. E) Immunoblotting in myoblasts of patient 1 showed decreased steady state levels for COX II and NDUFB8. Blotting with
antibodies against the complex II 70 kDa subunit and β actin showed equal loading. F) BN-PAGE in myoblasts of patient 1 showed severely decreased complexes I and IV and 3
additional bands with complex V antibodies, however complex III was normal. G) In-gel activities of complexes I and IV were decreased in myoblasts of patient 1, and complex
V was slightly reduced, but showed an extra band.
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subtle through the second decade, although acute metabolic crisis
and respiratory arrest lead to death in one patient after short anaes-
thesia for MRI (Tucker et al., 2011). The very brief description of 2 fur-
ther patients (Haack et al., 2012) did not allow us to make
assumption on the clinical severity.
Here we describe 2 sisters with compound heterozygous muta-
tions in theMTFMT gene leading to combined RC deficiency. Similarly
to the patients reported by Tucker et al., both sisters had normal de-
velopment in their early years, the first clinical investigations took
place at 9 and 5 years of age. The first symptoms were an impaired
speech and mild cognitive delay, while motor symptoms and ataxia
were subtle and became obvious in a later stage of the disease.
Brain MRI detected signs typical for Leigh syndrome in patient 1,
but was normal in patient 2 at 4 years of age, suggesting that MRI
may not be positive in the early phase of the disease.
One of the mutations identified in our patients, the nonsense muta-
tion c.994C>T, p.R332Xhas been previously reported in compoundhet-
erozygous state with another nonsense mutation (c.626C>T/
p.Arg181SerfsX5) (Haack et al., 2012). The second mutation c.452C>T,
p.Pro151Leu is novel, leads to the exchange of a well conserved amino
acid and is predicted to be disease causing (MutationTaster). It
has not been detected in the international SNP databases and in the
1000 genome database, and was absent in 256 ethnically matched
normal Caucasian control chromosomes. The clinical presentation
co-segregated with the compound heterozygous mutations within the
family. The pathogenicity was verified by the lack of detectable MTFMT
protein on immunoblotting (myoblasts of patient 1). Mitochondrial
proteins showed decreased steady state levels in myoblasts of patient
1 on immunoblotting and BN-PAGE detected a severely abnormal
pattern with decreased complexes I and IV and several abnormal
smaller bands stained with complex V antibodies. These findings were
keeping with the combined RC defect in skeletal muscle. High resolu-
tion Northern blotting showed normal steady state of mt-tRNAMet,
suggesting that the defect in formylation does not affect mt-RNAMet
stability.
How can we explain the combined RC defect in MTFMT deficiency?
In metazoan mitochondria, after aminoacylation of tRNAMet has
occurred, Met-tRNAMet is used for both translation initiation and elon-
gation. This is unlike its bacterial counterpart whose translational
machinery contains individual tRNAMet molecules for each role
(Tucker et al., 2011). In order to initiate translation in humans, a propor-
tion of Met-tRNAMet is formylated by mitochondrial methionyl-tRNA
formyltransferase (MTFMT) producing fMet-tRNAMet. The translation
initiation factor (IF-2mt) has a high affinity for fMet-tRNAMet and
promotes its binding to the mitochondrial ribosome (Spencer and
Spremulli, 2004). However, if Met-tRNAMet binds to EFTu before it is
formylated, it acts as an elongator tRNA. This partitioning mechanism
requires that IF-2mt strongly discriminates against Met-tRNAMet and
that EF-Tumt preferentially binds Met-tRNAMet (Spencer and Spremulli,
2004). Based on this hypothesis a defect in Met-tRNAMet formylation
would affect mitochondrial translation, although 35S methionine label-
ling in our patient showed onlymild abnormalities (patient 12 in Kemp
et al., 2011). This result is in contrast with the severe impairment on
BN-PAGE, suggesting that there is still more to discover about the
disease mechanism.5. Conclusions
Mutations in MTFMT should be screened in patients with Leigh
syndrome and combined respiratory chain deficiency. Exome se-
quencing is a very powerful diagnostic tool, and its value in clinical
medicine is enormous, however it can only be optimally exploited
if combined with detailed phenotyping. The selection of primary dis-
ease causing changes can be facilitated by functional studies.Acknowledgements
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